Litcius/Paper detail

Transcription factor-mediated regulation of the BCRP/<i>ABCG2</i>efflux transporter: a review across tissues and species

Ludwik Gorczyca, Lauren M. Aleksunes

2020Expert Opinion on Drug Metabolism & Toxicology39 citationsDOIOpen Access PDF

Abstract

Introduction: The breast cancer resistance protein (BCRP/ABCG2) is a member of the ATP-binding cassette superfamily of transporters. Using the energy garnered from the hydrolysis of ATP, BCRP actively removes drugs and endogenous molecules from the cell. With broad expression across the liver, kidney, brain, placenta, testes, and small intestines, BCRP can impact the pharmacokinetics and pharmacodynamics of xenobiotics.Areas covered: The purpose of this review is to summarize the transcriptional signaling pathways that regulate BCRP expression across various tissues and mammalian species. We will cover the endobiotic- and xenobiotic-activated transcription factors that regulate the expression and activity of BCRP. These include the estrogen receptor, progesterone receptor, peroxisome proliferator-activated receptor, constitutive androstane receptor, pregnane X receptor, nuclear factor e2-related factor 2, and aryl hydrocarbon receptor.Expert opinion: Key transcription factors regulate BCRP expression and function in response to hormones and xenobiotics. Understanding this regulation provides an opportunity to improve pharmacotherapeutic outcomes by enhancing the efficacy and reducing the toxicity of drugs that are substrates of this efflux transporter.

Topics & Concepts

Pregnane X receptorAryl hydrocarbon receptorAbcg2Constitutive androstane receptorNuclear receptorTranscription factorXenobioticBiologyPharmacologyEffluxReceptorTransporterCell biologyATP-binding cassette transporterBiochemistryGeneEnzymeDrug Transport and Resistance MechanismsPharmacological Effects and Toxicity StudiesPregnancy and Medication Impact